SYNERGY-201: SX-682 + Enzalutamide in Abiraterone-Resistant mCRPC

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC), the SYNERGY-201 Trial
Principal Investigator
Headshot of Andrew John Armstrong
Professor of Medicine
Protocol Number
IRB: PRO00113209
NCT: NCT06228053
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL